linkedin

Press Releases

Press Releases

Samsung Biologics receives the Terra Carta Seal in recognition of the company’s commitment to creating a sustainable future

Samsung-Biologics-receives-Terra-Carta-Seal-image.png

• Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal.

• The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets.

• Designed by Sir Jony Ive, the Terra Carta Seal embodies the vision and ambition of His Majesty King Charles III and the Terra Carta, as a recovery plan for Nature, People and Planet. 

• The Terra Carta Seal is underpinned by Corporate Knights’ Annual Global 100 Top Sustainable Corporations List and the wider principles of the Terra Carta.

 

Incheon, S. Korea and London, England, 11th January 2023 - Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), was awarded the Sustainable Markets Initiative’s Terra Carta Seal.

 

The Terra Carta Seal, launched at COP26 by His Majesty King Charles III when he was Prince of Wales, recognises global companies that are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. It is being awarded to companies whose ambitions are aligned with those of the Terra Carta, a recovery plan for Nature, People and Planet, launched in January 2021.

 

Samsung Biologics affirmed its commitment to achieving net zero greenhouse gas emissions across its direct operations and supply chain by 2050 or earlier as part of its global response to climate change.

 

Due to the complex nature of bioprocessing, the company’s environmental management strategy outlines a number of core activities to reduce emissions, including process energy optimization, transitioning to renewable energy by investing in solar panels and utilizing external resources, converting to zero emission vehicles, and minimizing the use of disposables in the manufacturing process through waste management and recycling.

 

Samsung Biologics is also working to drive successful decarbonization by committing to 100% renewable power through the Climate Group’s RE100 initiative and adopting the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD) in reporting its climate actions progress.

 

John Rim, CEO and President, Samsung Biologics said: “We are honoured to be recognized with the Terra Carta Seal by the Sustainable Markets Initiative for Samsung Biologics’ contribution in working alongside our industry peers for this global effort. Healthcare is at a pivotal moment and through our collaborative efforts, we can contribute to shaping climate-resilient practices to influence and help shape policy across the pharmaceutical and healthcare sectors.”

 

Brian Moynihan, Co-Chair, Sustainable Markets Initiative said: “The SMI brings CEOs together to work on the shared goals of accelerating our transition to a sustainable future.  I congratulate those organizations recognized with the 2022 Terra Carta Seal and thank them for their commitment to sustainable markets.”

 

The Terra Carta Seal acknowledges that each industry faces unique challenges in its transition to a sustainable future and they are all at different stages of their journey. And all industries and companies must be supported as they take steps in a more positive direction. At the same time, an accelerated pace is required if we are to achieve a 1.5-degree target, protect and restore biodiversity and benefit the lives and livelihoods of current and future generations. 

 

Alongside its work to eliminate carbon emissions from its own operations, Samsung Biologics is engaging its suppliers as part of a broader initiative by the Supply Chains Working Group within the Sustainable Markets Initiative’s Health Systems Task Force to reduce direct emissions and identify carbon reduction options with the goal of reaching net zero in its supply chain. Last month, the Task Force announced joint action at COP27 to achieve near-term emissions reduction targets and published commitments to decarbonize through a series of whitepapers outlining practical recommendations and scalable actions for health systems stakeholders.

 

Sir Jony Ive and his creative team at LoveFrom created a physical and animated seal engineered with paper that is both simple and beautifully crafted. The design combines a host of natural references including oak leaves, fern, magnolia and honeybees and intricate patterns both in nature and in the arts, creating a visual celebration which reflects the power of and reverence for nature that is at the heart of the Terra Carta.

 

For more details and continuous updates on sustainability activities, please visit the Samsung Biologics’ Sustainability page.

Samsung-Biologics-receives-Terra-Carta-Seal-image.png

• Samsung Biologics is one of 19 companies to have been awarded the 2022 Terra Carta Seal.

• The Terra Carta Seal recognises global companies which are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets.

• Designed by Sir Jony Ive, the Terra Carta Seal embodies the vision and ambition of His Majesty King Charles III and the Terra Carta, as a recovery plan for Nature, People and Planet. 

• The Terra Carta Seal is underpinned by Corporate Knights’ Annual Global 100 Top Sustainable Corporations List and the wider principles of the Terra Carta.

 

Incheon, S. Korea and London, England, 11th January 2023 - Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), was awarded the Sustainable Markets Initiative’s Terra Carta Seal.

 

The Terra Carta Seal, launched at COP26 by His Majesty King Charles III when he was Prince of Wales, recognises global companies that are driving innovation and demonstrating their commitment to, and momentum towards, the creation of genuinely sustainable markets. It is being awarded to companies whose ambitions are aligned with those of the Terra Carta, a recovery plan for Nature, People and Planet, launched in January 2021.

 

Samsung Biologics affirmed its commitment to achieving net zero greenhouse gas emissions across its direct operations and supply chain by 2050 or earlier as part of its global response to climate change.

 

Due to the complex nature of bioprocessing, the company’s environmental management strategy outlines a number of core activities to reduce emissions, including process energy optimization, transitioning to renewable energy by investing in solar panels and utilizing external resources, converting to zero emission vehicles, and minimizing the use of disposables in the manufacturing process through waste management and recycling.

 

Samsung Biologics is also working to drive successful decarbonization by committing to 100% renewable power through the Climate Group’s RE100 initiative and adopting the recommendations of the Task Force on Climate-Related Financial Disclosures (TCFD) in reporting its climate actions progress.

 

John Rim, CEO and President, Samsung Biologics said: “We are honoured to be recognized with the Terra Carta Seal by the Sustainable Markets Initiative for Samsung Biologics’ contribution in working alongside our industry peers for this global effort. Healthcare is at a pivotal moment and through our collaborative efforts, we can contribute to shaping climate-resilient practices to influence and help shape policy across the pharmaceutical and healthcare sectors.”

 

Brian Moynihan, Co-Chair, Sustainable Markets Initiative said: “The SMI brings CEOs together to work on the shared goals of accelerating our transition to a sustainable future.  I congratulate those organizations recognized with the 2022 Terra Carta Seal and thank them for their commitment to sustainable markets.”

 

The Terra Carta Seal acknowledges that each industry faces unique challenges in its transition to a sustainable future and they are all at different stages of their journey. And all industries and companies must be supported as they take steps in a more positive direction. At the same time, an accelerated pace is required if we are to achieve a 1.5-degree target, protect and restore biodiversity and benefit the lives and livelihoods of current and future generations. 

 

Alongside its work to eliminate carbon emissions from its own operations, Samsung Biologics is engaging its suppliers as part of a broader initiative by the Supply Chains Working Group within the Sustainable Markets Initiative’s Health Systems Task Force to reduce direct emissions and identify carbon reduction options with the goal of reaching net zero in its supply chain. Last month, the Task Force announced joint action at COP27 to achieve near-term emissions reduction targets and published commitments to decarbonize through a series of whitepapers outlining practical recommendations and scalable actions for health systems stakeholders.

 

Sir Jony Ive and his creative team at LoveFrom created a physical and animated seal engineered with paper that is both simple and beautifully crafted. The design combines a host of natural references including oak leaves, fern, magnolia and honeybees and intricate patterns both in nature and in the arts, creating a visual celebration which reflects the power of and reverence for nature that is at the heart of the Terra Carta.

 

For more details and continuous updates on sustainability activities, please visit the Samsung Biologics’ Sustainability page.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION